Program/Timetable
25th JSSX Annual Meeting in Tokyo
| Date |
October, 7 (Thu) - 9 (Sat), 2010
The public lecture is held on October, 6 (Wed), 2010 |
| Venues |
OMIYA Sonic City |
Meeting
Chairman |
Masahiro Hayashi, Ph.D.
(School of Pharmacy, Tokyo University of Pharmacy and Life Sciences) |
Meeting
Theme |
The Role of Drug Metabolism and Pharmacokinetics on Bridging Drug Discovery/Development and Clinical Research |
President’s Lecture
Oct., 8 (Fri.), 2010 14:40-15:05
Ken-ichi Inui
Kyoto Pharmaceutical University
TOWARD INTERNATIONALIZATION OF JSSX
Distinguished Lecture
- Oct., 8 (Fri.), 2010 13:40 - 14:40
Hiroki Ueda
RIKEN CDB
SYSTEMS BIOLOGY OF MAMMALIAN CIRCADIAN CLOCKS
- Oct., 9 (Sat.), 2010 11:30 - 12:30
Thomas A. Baillie
Dean of the School of Pharmacy at the University of Washington in Seattle, WA.
CHEMICALLY REACTIVE METABOLITES IN DRUG DISCOVERY AND LEAD
OPTIMIZATION
JSSX 25th Anniversary Symposium
Oct., 7 (Thu.), 2010 13:40-17:50
"Towards the Next Stage of DMPK Research by Integrating Uncovered Roles of Enzymes and Transporters – Challenges for Innovative Drug Discovery and Pharmacotherapy -"
13:40 - 13:50 MEMORY OF JSSX 25th ANNIVERSARYTohoku University Yasushi Yamazoe
13:50 - 13:55 INTRODUCTION OF THIS SYMPOSIUMKanazawa University Ikumi Tamai
13:55 - 14:35 TARGETED RADIONUCLIDE THERAPY - PRACTICE OF TARGETING CONFIRMATIVE THERAPY, AN INDIVIDUALIZED IMAGE-BASED TREATMENTKanazawa University Seigo Kinuya
14:35 - 15:25 MOLECULAR IMAGING ESPECIALLY PET - A USEFUL TOOL FOR IN VIVO MEASUREMENTS IN DRUG DEVELOPMENTUppsala University Bengt Langstrom
15:25 - 15:55 APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC(PBPK) MODELING AND CLEARANCE CONCEPT TO THE ANALYSIS OF TRANSPORTER-MEDIATED DISTRIBUTION AND CLEARANCE OF DRUGS IN HUMANThe University of Tokyo Yuichi Sugiyama
15:55 - 16:25 HUMAN DRUG METABOLITES AND INTERACTIONS MEDIATED POLYMORPHIC DRUG-METABOLIZING ENZYMESShowa Pharmaceutical University Hiroshi Yamazaki
16:25 - 16:55 PRECLINICAL STUDIES ON DRUG METABOLISM AND PHARMACOKINETICS IN STRATEGIC DRUG DISCOVERY FOR SUCCESSFUL DEVELOPMENT OF NEW DRUGSTaiho Pharmaceutical Co., Ltd. Masato Chiba
16:55 - 17:45 SCIENTIFIC PERSPECTIVE ON CYP- AND TRANSPORTER- BASED DRUG-DRUG INTERACTIONS: IMPACT ON DRUG EXPOSURE/RESPONSE, LABELING AND CLINICAL DECISIONSFDA Shiew-Mei Huang
17:45 - 17:50 CLOSING REMARKShionogi & Co., Ltd. Takahiko Baba
Symposium
S1 Oct., 7 (Thu.), 2010 9:00-11:30
"JSSX Symposium for the Success in Drug Development 2nd Symposium – PK/PD Based Functional Linkage for Drug Discovery and Development"
Organizer：Shinji Yamashita & Eiichi Fuse
9:00 - 9:10 OVERVIEWSetsunan University Shinji Yamashita
9:10 - 9:40 PK/PD, BIOMARKER + MODEL-BASED DRUG DEVELOPMENT WHERE TO START?Boehringer Ingelheim Pharma KG Ulrich Roth
9:40 - 10:05 MEDCHEM MEETS ADMEOno Pharmaceutical Co., LTD. Atsushi Naganawa
10:05 - 10:30 ADME RESEARCH IN DRUG DEVELOPMENT OF ANTI-CANCER AGENTSTaiho Pharmaceutical Co., Ltd. Kunihiro Yoshisue
10:30 - 10:55 FORMULATION DESIGN AND PHARMACOKINETICS CONTROLAstellas Pharma Inc. Kazuhiro Sako
10:55 - 11:20 COOPERATION OF DMPK AND TOX FOR DISCOVERY AND DEVELOPMENT OF SAFE DRUGShionogi & Co., Ltd. Takahiko Baba
11:20 - 11:30 CLOSINGKyowa Hakko Kirin Co., Ltd. Eiichi Fuse
S2 Oct., 7 (Thu.), 2010 9:00-11:30
“Drug Metabolism Research in Asia: Orphan P450 Enzymes, Natural Products, and Human Metabolite Formations"
Organizer：Hiroshi Yamazaki & Yune-Fang Ueng
ROLES OF P450 1A AND 3A ENZYMES INVOLVED IN REACTIVE METABOLITE FORMATIONS
Showa Pharmaceutical University Hiroshi Yamazaki
GENERATION OF HUMAN DRUG METABOLITES BY BACTERIAL CYTOCHROME P450 BM3 MUTANTS
Chonnam National University Chul-Ho Yun
ELUCIDATING THE FUNCTION OF ORPHAN HUMAN CYTOCHROME P450S
Chinese Academy of Sciences Zhong-Liu Wu
SAFROLE AND HUMAN CYTOCHROME P450: BIOACTIVATION, INHIBITION, AND INDUCTION
National Research Institute of Chinese Medicine Yune-Fang Ueng
CYP3A5, GENDER, AND INTESTINAL ENZYME EXPRESSION AFFECT PHARMACOKINETICS OF NIFEDIPINE
National Cheng Kung University Jin-ding Huang
S3 Oct., 8 (Fri.), 2010 9:00-11:30
“Transporter as the Cause of Disease and the Target of Pharmacotherapy"
Organizer：Mikihisa Takano, Setsuko Komuro, Toshiharu Horie & Yoshiharu Deguchi
9:00 - 9:10 OPENING REMARKHiroshima University Mikihisa Takano
9:10 - 9:40 IDENTIFICATION OF ABCG2/BCRP AS MAJOR CAUSE FOR GOUTNational Defense Medical College Hirotaka Matsuo
9:40 - 10:10 DISCOVERY AND IDENTIFICATION OF NOVEL DRUG TARGETS BASED ON HE ANALYSIS OF THE EXPRESSION AND FUNCTION OF DISEASE-ASSOCIATED ABC TRANSPORTERSKumamoto University Tsuyoshi Shuto
10:10 - 10:40 NPC1L1, A PHARMACOLOGICAL TARGET OF DYSLIPIDEMIAThe University of Tokyo Hospital Tappei Takada
10:40 - 11:10 RESEARCH ON TRANSPORTERS IN DRUG DISCOVERY AND DEVELOPMENTDaiichi Sankyo Co., Ltd. Noriko Okudaira
11:10 - 11:15 CLOSING REMARKTeikyo University Yoshiharu Deguchi
S4 Oct., 8 (Fri.), 2010 9:00-11:30
“Fundamentals and Prospects of UDP-glucuronyltransferase (UGT) in Drug Development"
Organizer：Akira Hiratsuka & Ken-ichirou Ogura
9:00 - 9:05 INTRODUCTIONTokyo University of Pharmacy and Life Sciences Akira Hiratsuka
9:05 - 9:30 NEW ASPECTS OF UDP-GLUCURONOSYLTRANSFERASERakuno Gakuen University Hiroshi Yokota
9:30 - 9:55 TRANSCRIPTIONAL REGULATION OF HUMAN UDP-GLUCURONOSYLTRANSFERASE UGT1A1 GENE EXPRESSION AND THE ALTERATION IN ITS PROTEIN EXPRESSION BY INTRACELLULAR FACTORS CONTROLLING CELL PROLIFERATIONUniversity of Shizuoka Junko Sugatani
9:55 - 10:20 DEVELOPMENT OF GLUCURONIDE PREPARATION SYSTEM FOR XENOBIOTIC METABOLITES USING GENETICALLY ENGINEERED BUDDING YEASTToyama Prefectural University Shinichi Ikushiro and Toshiyuki Sakaki
10:20 - 10:45 PROTEIN-PROTEIN ASSOCIATION OF CYTOCHROME P450 AND UDP-GLUCURONOSYLTRANSFERASE: ITS RELEVANCE TO ENZYME FUNCTIONKyushu University Yuji Ishii
10:45 - 11:10 EVALUATION OF IN VITRO GLUCURONIDATIONFaculty of Pharmaceutical Sciences, Kanazawa University Miki Nakajima
11:00 - 11:30 SUMMARIZATION & DISCUSSION
Round Table
R1 Oct., 9 (Sat.), 2010 9:00-11:20
“Chemically Reactive Drug Metabolites in Drug Discovery and Development"
Organizer：Masato Chiba & Thomas A. Baillie
STRATEGY FOR PREDICTION OF DRUG-DRUG INTERACTIONS CAUSED BY MECHANISM-BASED INHIBITION IN THE DRUG DISCOVERY THROUGH DEVELOPMENT STAGES
Chugai Pharmaceutical Co., Ltd. Nobuo Sekiguchi
CHRACTERIZATION OF REACTIVE METABOLITES BY HIGH-RESOLUTION MASS SPECTROMETRY IN DRUG DISCOVERY
Taiho Pharmaceutical Co., Ltd. Tomoyuki Ohe
A ZONE CLASSIFICATION SYSTEM FOR RISK ASSESSMENT OF IDIOSYNCRATIC DRUG TOXICITY USING DAILY DOSE AND COVALENT BINDING
Daiichi Sankyo Co., Ltd. Shintaro Nakayama
APPROACHES TO PREDICT IDIOSYNCRATIC AND IMMUNE-MEDIATED DRUG-INDUCED LIVER INJURY
Kanazawa University Tsuyoshi Yokoi
R2 Oct., 9 (Sat.), 2010 13:40-16:00
“The Significance and Issues of Evaluating Intestinal Metabolism in Drug Discovery and Development – Focused on CYP and UGT"
Organizer：Toshiyuki Kume & Hiroshi Komura
CYP AND UGT EXPRESSED IN INTESTINE AND THEIR SPECIES DIFFERENCES
Kanazawa University Miki Nakajima
QUANTITATIVE ASSESSMENT OF SMALL INTESTINAL METABOLSIM: CURRENT STATE AND ISSUES
Tokyo University of Pharmacy and Life Sciences Takashi Mizuma
THE IMPACT OF INTESTINAL GLUCURONIDATION ON THE PHARMACOKINETICS OF RALOXIFENE IN RATS
Mitsubishi Tanabe Pharma Corporation Keigo Kosaka
THE INTESTINAL METABOLISM IN HUMANS AND MONKEYS, DOES MONKEY PREDICT HUMAN PK? OR JUST EVOLVED
Astellas Research Institute of America LLC. Takafumi Akabane
ANIMAL MODELS FOR PREDICTING INTESTINAL METABOLISM OF DRUDS IN HUMANS
Taiho Pharmacetical CO., LTD. Jiro Kuze
Forum 2010
Oct., 9 (Sat.), 2010 13:40-16:40
“The Status and Future Perspective of Protein Drugs: Their Safety, Pharmacokinetics and Approval"
Organizer：Hideyuki Yamada & Kouji Izumi
GLOBAL/DOMESTIC MARKET AND DEVELOPMENT STATUS OF BIOLOGICS
Takeda Bio Development Center Eiji Takahara
REGULATORY CMC ISSUES OF PROTEIN DRUGS
Kyoto University Koji Kawakami
QUALITY AND SAFETY EVALUATION OF BIOTECHNOLOGY-DERIVED PHARMACEUTICALS
National Institute of Health Sciences Toru Kawanishi
THE IMPACT OF CLINICALPHARMACOLOGY APPROACHES IN MONOCLONAL ANTIBODY DEVELOPMENT
Chugai Pharmaceutical Co., ltd. Kimio Terao
PHARMACOKINETIC STUDIES OF PROTEIN, PEPTIDE AND ANTIBODY DRUGS REGULATIONS AND OPERATIONS
Takasaki University of Health and Welfare Takuo Ogihara
CLINICAL TRIALS FOR DEVELOPMENTS OF BIOLOGIC DRUGS SUCH AS PROTEINS, PEPTIDES AND ANTIBODIES
Kitasato University East Hospital Yuji Kumagai
SummaryKyushu University Hideyuki Yamada
Timetable
